Community Investing Ideas

Global Weekly Picks

US$395
FV
6.5% undervalued intrinsic discount
10.63%
Revenue growth p.a.
3.3k
users have viewed this narrative
26users have liked this narrative
3users have commented on this narrative
25users have followed this narrative
US$30
FV
1.2k% overvalued intrinsic discount
-28.34%
Revenue growth p.a.
5k
users have viewed this narrative
26users have liked this narrative
7users have commented on this narrative
31users have followed this narrative
US$1.48k
FV
35.4% undervalued intrinsic discount
18.00%
Revenue growth p.a.
2k
users have viewed this narrative
5users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
RM 0.13
73.1% overvalued intrinsic discount
Fair Value
Revenue
N/A
Profit Margin
0.9%
Future PE
149.08x
Price in 2031
RM 0.22
LUCD logo
Lucid Diagnostics

Poised for success

Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Read more

View narrative
7
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
US$5
77.0% undervalued intrinsic discount
Fair Value
Profit Margin
13.44%
Future PE
24.75x
Price in 2031
US$7.33
RM 0.17
23.5% undervalued intrinsic discount
Fair Value
Revenue
20% p.a.
Profit Margin
5.91%
Future PE
24.17x
Price in 2031
RM 0.24